The first challenge was to createthe wand. The device would need to do a lot: It’s impossible for a person to see their own cervix, so the user would have to be able to find the cervix blind, collect the sample themselves, and remove the wand from their bodies without contaminating it on other parts of their anatomy. Because this is something users are likely to do in their bathrooms, where there is no space to lie down, they would need to be able to use the device while standing—and with one hand. From the beginning, the IDEO team set out to design functional, testable prototypes to make sure the idea was viable, and incorporate diverse voices into the research process, including trans, minority, and disabled women.
Because the product is meant for people who aren’t medical professionals, the team worked to design something as simple, intuitive, and unintimidating as possible. They used a 3-D printer to create multiples of every prototype, autoclaves to make sure that the designs they were creating were sterile, and leaned into shapes women are already used to, like the cylindrical shape of a tampon. The wand they created has that same basic form, but with a soft sponge that the user can deploy with the turn of a dial to collect the sample, then close to protect it from contamination on the way out of the body.
With working prototypes in hand, Teal set out to test their efficacy. In an initial study with 220 participants varying in age, race, socioeconomic status, and geography, Teal found that not only were participants able to successfully self-collect samples, they also preferred them over the speculum, the device doctors typically use during a screening. Some 92 percent said if they knew the results were equal they would prefer self-collection, while 87 percent reported they would stay current with screening if Teal Wand was an option. Self-collection took the vast majority under two minutes to complete, and 97% of study participants reported it was very easy or easy to use. The Teal Wand recently received a patent for its unique design.
The IDEO team also worked on the packaging and unboxing experience, which plays an important role in supporting the user through the self-screening process. The team built in thoughtful design cues to give users reassurance that they are using the wand correctly, and to provide the same level of confidence they would have in the results of an in-clinic screening.
In January 2023, Teal raised an $8.8 million seed round from Serena Ventures, Emerson Collective, and Metrodora, and later that year, launched a nationwide clinical trial with leading health organizations including Johns Hopkins University, Yale University, the University of Colorado, Washington University, and others to support FDA submission and approval. It’s an enormous step toward its North Star: catching cervical cancer earlier and saving lives.
